Immunome(IMNM) - 2020 Q3 - Quarterly Report

General Information Form 10-Q Details This document is a Quarterly Report on Form 10-Q for Immunome, Inc. for the period ended September 30, 2020, detailing its corporate status and stock information - The report is a Quarterly Report on Form 10-Q for the period ended September 30, 2020[2] Registrant Information | Detail | Value | | :-------------------------------- | :----------- | | Registrant Name | Immunome, Inc. | | State of Incorporation | Delaware | | Trading Symbol | IMNM | | Market | The Nasdaq Capital Market | | Filer Status | Non-accelerated filer, Smaller reporting company, Emerging growth company | - As of October 31, 2020, there were 10,541,629 shares of common stock outstanding[5] PART I – FINANCIAL INFORMATION Item 1. Financial Statements. This section presents Immunome, Inc.'s unaudited condensed financial statements, including balance sheets, statements of operations, changes in equity, and cash flows, along with comprehensive explanatory notes Condensed Balance Sheets The condensed balance sheets show a significant increase in total assets and liabilities from December 31, 2019, to September 30, 2020, primarily driven by an increase in cash and the recognition of a warrant liability Condensed Balance Sheet Highlights (in thousands) | Metric | Sep 30, 2020 | Dec 31, 2019 | | :-------------------------------- | :----------- | :----------- | | Cash | $6,744 | $2,543 | | Total current assets | $7,483 | $3,122 | | Total assets | $11,983 | $5,060 | | Total current liabilities | $5,406 | $1,665 | | Warrant liability | $7,071 | $— | | Total liabilities | $12,699 | $1,796 | | Total stockholders' deficit | $(49,085) | $(35,630) | Condensed Statements of Operations The company reported increased net losses for both the three and nine months ended September 30, 2020, compared to the prior year, largely due to a significant non-cash charge from the change in fair value of warrant liability Condensed Statements of Operations Highlights (in thousands) | Metric | 3 Months Ended Sep 30, 2020 | 3 Months Ended Sep 30, 2019 | 9 Months Ended Sep 30, 2020 | 9 Months Ended Sep 30, 2019 | | :---------------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | Research and development | $1,644 | $2,234 | $5,651 | $6,391 | | General and administrative | $1,174 | $486 | $2,537 | $1,069 | | Total operating expenses | $2,818 | $2,720 | $8,188 | $7,460 | | Loss from operations | $(2,818) | $(2,720) | $(8,188) | $(7,460) | | Change in fair value of warrant liability | $(5,549) | $— | $(5,549) | $— | | Net loss | $(8,377) | $(2,737) | $(13,764) | $(7,522) | | Net loss per share (basic and diluted) | $(7.52) | $(2.50) | $(12.44) | $(6.88) | Condensed Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit The statements detail changes in convertible preferred stock and stockholders' deficit, reflecting the issuance of Series A convertible preferred stock, share-based compensation, exercise of stock options, and net losses for the periods presented Changes in Convertible Preferred Stock and Stockholders' Deficit (9 Months Ended Sep 30, 2020, in thousands) | Item | Series A Amount | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Deficit | | :-------------------------------------------------------------------------------- | :---------------- | :------------------------- | :------------------ | :-------------------------- | | Balance at Dec 31, 2019 | $38,894 | $927 | $(36,557) | $(35,630) | | Sale of Series A convertible preferred stock and warrants (net) | $9,475 | $— | $— | $— | | Share-based compensation expense | $— | $302 | $— | $302 | | Exercise of stock options | $— | $7 | $— | $7 | | Net loss | $— | $— | $(13,764) | $(13,764) | | Balance at Sep 30, 2020 | $48,369 | $1,236 | $(50,321) | $(49,085) | Condensed Statements of Cash Flows Cash flows from operating activities remained negative, while financing activities provided significant cash, primarily from the sale of convertible preferred stock and a PPP loan, leading to a net increase in cash and restricted cash for the nine months ended September 30, 2020 Condensed Statements of Cash Flows Highlights (9 Months Ended Sep 30, in thousands) | Cash Flow Activity | 2020 | 2019 | | :-------------------------------- | :----- | :----- | | Net cash used in operating activities | $(6,072) | $(7,021) | | Net cash used in investing activities | $(540) | $(166) | | Net cash provided by financing activities | $10,813 | $6,345 | | Net increase (decrease) in cash and restricted cash | $4,201 | $(842) | | Cash and restricted cash at end of period | $6,844 | $860 | - Non-cash financing activities for 2020 included $1.522 million fair value of liability-classified warrants issued and $2.221 million IPO costs included in accounts payable[21] Notes to Condensed Financial Statements These notes provide detailed explanations of the company's business, significant accounting policies, financial instrument valuations, debt, equity transactions, and other commitments, offering crucial context for the financial statements Note 1. Nature of the business and basis of presentation Immunome, Inc. is a biotechnology company focused on immunotherapies, operating as an early-stage company with a history of net losses, whose recent IPO significantly improved its liquidity, alleviating prior going concern concerns - Immunome, Inc. is a biotechnology company focused on identifying novel cancer and infectious disease immunotherapies using a patented B cell immortalization process[23] - The company has incurred net losses since inception, with a net loss of $13.8 million for the nine months ended September 30, 2020, and an accumulated deficit of $50.3 million[26] - On October 6, 2020, the company closed its IPO, issuing 3,250,000 shares at $12.00/share, generating net proceeds of $41.7 million, which, combined with existing cash, is expected to fund operations into Q1 2022, alleviating prior going concern doubts[25][27] Note 2. Summary of significant accounting policies This note outlines the accounting principles used, including GAAP compliance, unaudited interim results, the impact of a reverse stock split, use of estimates, fair value measurements, government contract funding as contra-R&D expense, warrant liability classification and valuation, research and development cost expensing, and net loss per share calculation using the two-class method - The financial statements are prepared in accordance with GAAP and include unaudited interim results[33][34] - A one-for-six reverse stock split was legally effective on September 22, 2020, retroactively adjusting all share and per share amounts[36] - Warrants to purchase Series A convertible preferred stock are classified as a liability and remeasured to fair value at each balance sheet date, with changes recognized in the statements of operations, and fair value is estimated using the Black-Scholes option pricing model[42][44][45] - Research and development costs are expensed as incurred, and amounts received under the U.S. Department of Defense expense reimbursement contract are accounted for as contra-research and development expenses[41][46] - Net loss per share is computed using the two-class method, excluding potentially dilutive securities when their effect is anti-dilutive[47][50] Note 3. Fair value measurements This note details the fair value measurements, specifically for the warrant liability, which is categorized as Level 3 due to the use of unobservable inputs, and which increased significantly during the nine months ended September 30, 2020 Fair Value Measurements (September 30, 2020, in thousands) | Liabilities | Total | Level 1 | Level 2 | Level 3 | | :-------------------------------- | :---- | :------ | :------ | :------ | | Warrant liability | $7,071 | $— | $— | $7,071 | | Total liabilities measured and recorded at fair value | $7,071 | $— | $— | $7,071 | Reconciliation of Change in Fair Value of Warrant Liability (9 Months Ended Sep 30, 2020, in thousands) | Item | Fair Value Measurements Using Significant Unobservable Inputs (Level 3) | | :-------------------------------- | :-------------------------------------------------------- | | Balance, December 31, 2019 | $— | | Issuance of warrants on June 2, 2020 | $1,522 | | Change in fair value of warrant liability | $5,549 | | Warrant liability, September 30, 2020 | $7,071 | Note 4. U.S. Department of Defense ("DoD") expense reimbursement contract In July 2020, the company entered into an OTA Agreement with the DoD for $13.3 million to develop Biosynthetic Convalescent Plasma (BCP) for COVID-19 treatment, recording $0.6 million as contra-research and development expense for the three and nine months ended September 30, 2020 - The company secured a $13.3 million OTA Agreement with the DoD in July 2020 to develop Biosynthetic Convalescent Plasma (BCP) for COVID-19[55] - Contra-research and development expense of $0.6 million was recorded for both the three and nine months ended September 30, 2020, related to this agreement[55] Note 5. Accrued expenses Accrued expenses significantly increased from December 31, 2019, to September 30, 2020, primarily due to IPO costs and higher compensation and related benefits Accrued Expenses (in thousands) | Category | Sep 30, 2020 | Dec 31, 2019 | | :-------------------------- | :----------- | :----------- | | IPO costs | $1,165 | $— | | Compensation and related benefits | $831 | $426 | | Research and development, and other | $334 | $240 | | Total | $2,330 | $666 | Note 6. Convertible promissory notes In 2019, the company issued $6.8 million in non-interest bearing convertible promissory notes, which automatically converted into 821,657 shares of Series A Preferred stock in November 2019 upon the completion of a Series A Preferred sale - From January to July 2019, the company issued $6.8 million in non-interest bearing convertible promissory notes[57] - These notes automatically converted into 821,657 shares of Series A Preferred stock in November 2019[58] Note 7. Equipment loan payables The company has equipment financing agreements with interest rates ranging from 9.03% to 12.08%, with future payments totaling $168,000 as of September 30, 2020, primarily due in 2021 - Equipment financing agreements have interest rates between 9.03% and 12.08%[60] Future Equipment Loan Payments (as of Sep 30, 2020, in thousands) | Years ending December 31, | Amount | | :-------------------------- | :----- | | 2020 (remaining 3 months) | $51 | | 2021 | $117 | | Total | $168 | | Less amounts representing interest | $(8) | | Total equipment loan payable | $160 | Note 8. Long-term debt In April 2020, the company secured a $0.5 million PPP loan under the CARES Act, bearing 1% interest, with payments deferred until October 2020, and the company intends to apply for loan forgiveness - On April 30, 2020, the company entered into a $0.5 million PPP loan agreement with Silicon Valley Bank under the CARES Act[62] - The loan matures in two years, bears 1% interest, and payments were deferred until October 30, 2020, with the company planning to apply for forgiveness[62] Future Principal Payments for Long-Term Debt (as of Sep 30, 2020, in thousands) | Years ending December 31, | Amount | | :-------------------------- | :----- | | 2020 (remaining 3 months) | $55 | | 2021 | $333 | | 2022 | $112 | | Total | $500 | | Less current portion of long-term debt | $(305) | | Long-term debt, net of current portion | $195 | Note 9. Commitments and contingencies The company has commitments related to an operating lease for office and laboratory space, with future minimum payments totaling $434,000 as of September 30, 2020, while capital leases for equipment ended in July 2020, and the company also has employment agreements and a 401(k) plan - The company leases office and laboratory space under a 62-month operating lease, with future minimum payments of $434,000 as of September 30, 2020[64][65] - Capital leases for laboratory equipment, with interest rates from 9.43% to 11.35%, concluded in July 2020[66] - The company maintains employment agreements with key personnel and a defined-contribution 401(k) plan for employees[67][68] Note 10. Convertible preferred stock and stockholders' deficit This note details the terms of Series A convertible preferred stock, including dividend, voting, liquidation, and conversion rights, and its classification as temporary equity, also describing common stock rights and the conversion of all preferred stock into common stock upon the IPO - In June 2020, the company sold 1,226,925 shares of Series A Preferred stock for $11.0 million gross proceeds and issued warrants to purchase 1,035,196 shares of Series A Preferred[70][71] - Series A Preferred stockholders have dividend participation rights (though none declared), voting rights on an as-converted basis, and liquidation preferences[72][73][74] - The Series A Preferred is convertible into common stock at $9.00 per share, with automatic conversion upon a public offering meeting specific criteria, and is classified as temporary equity due to contingent redemption events outside the company's control[75][76] - Upon the IPO closing on October 6, 2020, all outstanding Series A Preferred stock converted into 5,670,184 shares of common stock[25][80] Note 11. Warrants to acquire shares of Series A convertible preferred stock The company issued 1,035,196 liability-classified warrants to acquire Series A convertible preferred stock in June 2020, which are valued using a Black-Scholes model and will convert to common stock warrants upon IPO completion - 1,035,196 liability-classified warrants to acquire Series A convertible preferred stock were issued in June 2020[83] - The fair value of these warrants is estimated using a Black-Scholes pricing model, incorporating inputs like volatility rate (79.0% on June 2, 2020; 81.9% on Sep 30, 2020), risk-free interest rate (0.2%), expected term (3.0 years), strike price ($9.00), and fair value of Series A preferred stock ($4.44 on June 2, 2020; $12.00 on Sep 30, 2020)[84] Note 12. Share-based compensation The company has various equity incentive plans (2008, 2018, 2020 Plans, and ESPP Plan) for granting stock options and other awards, with share-based compensation expense increasing significantly in 2020, and unrecognized compensation cost for unvested options totaling $1.5 million as of September 30, 2020 - The company operates under the 2008, 2018, and 2020 Equity Incentive Plans, and adopted the 2020 Employee Stock Purchase Plan (ESPP Plan)[85][86] Share-Based Compensation Expense (in thousands) | Category | 3 Months Ended Sep 30, 2020 | 3 Months Ended Sep 30, 2019 | 9 Months Ended Sep 30, 2020 | 9 Months Ended Sep 30, 2019 | | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | General and administrative | $78 | $1 | $208 | $5 | | Research and development | $39 | $— | $94 | $6 | | Total | $117 | $1 | $302 | $11 | - Unrecognized compensation cost for unvested options was $1.5 million as of September 30, 2020, to be recognized over an estimated 2.82 years[90] - Stock options outstanding at September 30, 2020, totaled 1,316,267 shares with a weighted-average exercise price of $0.97 and an aggregate intrinsic value of $14.5 million[91][93] Note 13. Related party transactions Related party transactions include license agreements, convertible promissory notes from existing investors, and a master services agreement with Broadband for advisory services, resulting in $0.1 million in general and administrative expenses for the three and nine months ended September 30, 2020 - Expenses with related parties from license agreements were de minimis for the three and nine months ended September 30, 2020[95] - In 2019, $3.8 million of convertible promissory notes were issued to existing preferred stock investors, which later converted to Series A Preferred shares[96] - The company pays Broadband Capital Partners LLC $20,000 per month for advisory services, totaling $0.1 million in general and administrative expenses for both the three and nine months ended September 30, 2020[97] Note 14. Subsequent events Subsequent to the reporting period, the company completed its IPO on October 6, 2020, raising $41.7 million net proceeds, with all outstanding convertible preferred stock and warrants converting into common stock, and the authorized common stock being increased - On October 6, 2020, the company closed its IPO, selling 3,250,000 shares at $12.00 per share, with underwriters exercising an option for an additional 487,500 shares, resulting in $41.7 million net proceeds[98] - Upon IPO closing, all outstanding convertible preferred stock converted into 5,670,184 shares of common stock, and warrants to purchase preferred stock converted into warrants to purchase common stock[98] - The company's authorized common stock was increased to 200,000,000 shares, and 10,000,000 shares of 'blank check' preferred stock were authorized[98] Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section provides management's perspective on the company's financial condition and operational results, highlighting its development stage, recent IPO, and the impact of the COVID-19 pandemic, detailing operating expenses, analyzing financial performance, discussing liquidity, funding requirements, critical accounting policies, and the implications of the JOBS Act Overview Immunome, Inc. is a development-stage biotechnology company with no product sales revenue to date, primarily funding operations through preferred stock sales, warrants, convertible notes, and a recent IPO, and continues to incur significant operating losses, requiring substantial additional financing for its preclinical and future clinical development - Immunome is a development-stage company with all programs at a preclinical stage, having generated no revenue from product sales to date[105] - The company has financed operations through $50.4 million from preferred stock/warrants and convertible notes, a $0.5 million PPP loan, and $41.7 million net proceeds from its October 2020 IPO[102][103] - Net losses were $8.4 million for the three months and $13.8 million for the nine months ended September 30, 2020, and the company expects continued significant operating losses and will need substantial additional financing beyond Q1 2022[105][106][112] COVID-19 Pandemic The COVID-19 pandemic has caused significant disruptions, leading Immunome to implement work-from-home policies and stringent safety measures for essential staff, and while no significant impact on operations or financial statements has been observed to date, future effects on development timelines, liquidity, and stock value remain uncertain - The COVID-19 pandemic has led to severe travel restrictions, social distancing, and stay-at-home orders, causing significant disruptions to economies and financial markets[113] - Immunome implemented a work-from-home policy for most employees and stringent safety measures for business-critical staff to maintain business continuity[114] - To date, there has not been a significant impact on the company's operations or financial statements, but future effects on development timelines, access to capital, and stock value are uncertain[32][114][115][116] Components of our results of operations This section defines the key components of the company's operating results: research and development expenses (expensed as incurred, including personnel, preclinical, manufacturing, and supplies, offset by DoD funding), general and administrative expenses (salaries, legal, professional fees), change in fair value of warrant liability (non-cash charge from remeasurement), and interest expense, net - Research and development expenses are expensed as incurred, covering personnel, preclinical development, manufacturing, and supplies, with DoD funding recognized as contra-R&D expense[117][120] - General and administrative expenses include salaries, legal fees, professional fees, and other operating costs, expected to increase with public company operations[121][122] - Change in fair value of warrant liability is a non-cash charge reflecting remeasurement of preferred stock warrants, which converted to common stock warrants post-IPO[123][125] Results of operations The company's results of operations show a significant increase in net loss for both the three and nine months ended September 30, 2020, primarily driven by a $5.5 million non-cash charge from the change in fair value of warrant liability, with research and development expenses decreasing for the nine-month period due to reduced outsourced services, while general and administrative expenses increased due to higher personnel and professional fees Operating Results (3 Months Ended Sep 30, in thousands) | Metric | 2020 | 2019 | Change | | :-------------------------------- | :----- | :----- | :----- | | Research and development | $1,644 | $2,234 | $(590) | | General and administrative | $1,174 | $486 | $688 | | Total operating expenses | $2,818 | $2,720 | $98 | | Loss from operations | $(2,818) | $(2,720) | $(98) | | Change in fair value of warrant liability | $(5,549) | $— | $(5,549) | | Net loss | $(8,377) | $(2,737) | $(5,640) | Operating Results (9 Months Ended Sep 30, in thousands) | Metric | 2020 | 2019 | Change | | :-------------------------------- | :----- | :----- | :----- | | Research and development | $5,651 | $6,391 | $(740) | | General and administrative | $2,537 | $1,069 | $1,468 | | Total operating expenses | $8,188 | $7,460 | $728 | | Loss from operations | $(8,188) | $(7,460) | $(728) | | Change in fair value of warrant liability | $(5,549) | $— | $(5,549) | | Net loss | $(13,764) | $(7,522) | $(6,242) | - Research and development expenses for the three months ended September 30, 2020, decreased by $0.6 million due to DoD contra-R&D expense, but increased slightly excluding this effect due to higher personnel and facility costs, offset by reduced outsourced services[128] - General and administrative expenses increased by $0.7 million for the three months and $1.5 million for the nine months ended September 30, 2020, primarily due to increased personnel-related costs and professional fees[130][136] Liquidity and capital resources The company has historically incurred significant operating losses and expects this trend to continue, and while the recent IPO provided substantial cash, additional financing will be required to fund ongoing research and development and growth strategies beyond Q1 2022, with cash flows reflecting significant cash used in operations and investing, offset by cash provided by financing activities - The company has incurred significant operating losses since inception and expects to continue doing so, requiring substantial additional financing for preclinical and clinical development[141][150] - As of September 30, 2020, cash was $6.7 million, supplemented by $41.7 million net IPO proceeds in October 2020, expected to fund operations into Q1 2022[142][151] Cash Flow Summary (9 Months Ended Sep 30, in thousands) | Cash Flow Activity | 2020 | 2019 | | :-------------------------------- | :----- | :----- | | Cash used in operating activities | $(6,072) | $(7,021) | | Cash used in investing activities | $(540) | $(166) | | Cash provided by financing activities | $10,813 | $6,345 | | Net increase (decrease) in cash and restricted cash | $4,201 | $(842) | - Future funding requirements depend on factors like the costs of developing the Immunome Discovery Engine, preclinical/clinical trials, intellectual property, regulatory approvals, and operating as a public company[152][153] Critical accounting policies and use of estimates This section outlines critical accounting policies requiring significant management judgment and estimates, including government contract funding, share-based compensation (using Black-Scholes and probability-weighted expected return methods), and warrant liability valuation (using Black-Scholes), noting that the IPO eliminates the need for estimates in valuing common stock and warrants - Government contract funding is accounted for as contra-research and development expenses[159] - Share-based compensation expense is recognized over the vesting period, with fair value estimated using the Black-Scholes model, relying on inputs like common stock fair value, volatility, and expected term[160][161] - Prior to May 2020, common and preferred stock were valued using a net asset approach and Option Pricing Method (OPM); from May to September 2020, the probability-weighted expected return method was used[162][164] - Warrant liability is valued using the Black-Scholes option pricing model, incorporating assumptions about the underlying Series A convertible preferred stock's fair value, contractual term, risk-free interest rate, and volatility[169][170] Recently issued accounting standards Management does not expect any recently issued accounting standards to significantly impact the company's financial position, operations, or cash flows - No recently issued accounting standards are expected to impact the company's financial position, operations, or cash flows[171] JOBS Act As an emerging growth company under the JOBS Act, Immunome is eligible for reduced disclosure requirements and has elected to use the extended transition period for complying with new or revised accounting standards, meaning it will adopt new standards at the same time as private companies - Immunome qualifies as an 'emerging growth company' under the JOBS Act, allowing for reduced disclosure requirements[172] - The company has elected to use the extended transition period for complying with new or revised accounting standards, adopting them at the same time as private companies[176] Off-balance sheet arrangements The company has no off-balance sheet arrangements as defined by SEC rules and regulations - The company does not have any off-balance sheet arrangements[177] Item 3. Quantitative and Qualitative Disclosures about Market Risk As a smaller reporting company, Immunome, Inc. is not required to provide quantitative and qualitative disclosures about market risk - The company, as a smaller reporting company, is not required to provide disclosures about market risk[178] Item 4. Controls and Procedures Management concluded that the company's disclosure controls and procedures were ineffective as of September 30, 2020, due to previously identified material weaknesses related to review processes and insufficient accounting personnel, and the company is actively remediating these weaknesses by implementing new controls and hiring experienced financial personnel - Management, including the CEO and CFO, concluded that disclosure controls and procedures were ineffective as of September 30, 2020[179] - Three material weaknesses were identified: lack of review of journal entries, lack of timely and effective review of financial statement account reconciliations, and insufficient accounting personnel[181][183] - Remediation efforts include implementing controls for journal entry and reconciliation reviews, hiring a full-time CFO and Corporate Controller, and engaging consultants[184] - The company acknowledges inherent limitations in control systems, providing reasonable, not absolute, assurance of effectiveness[185] PART II – OTHER INFORMATION Item 1. Legal Proceedings Immunome, Inc. is not currently involved in any material legal proceedings, though it may encounter ordinary course legal matters from time to time - The company is not currently a party to any material legal proceedings[188] Item 1A. Risk Factors There have been no material changes to the risk factors previously disclosed in the company's IPO prospectus filed on October 5, 2020 - No material changes to the risk factors described in the IPO prospectus filed on October 5, 2020[189] Item 2. Unregistered Sales of Equity Securities and Use of Proceeds During the quarter ended September 30, 2020, Immunome granted stock options and issued common stock upon option exercises, relying on Rule 701 and Section 4(a)(2) exemptions, and the company also detailed the use of proceeds from its October 2020 IPO, which generated $33.8 million net of other offering expenses - During Q3 2020, the company granted options to purchase 301,647 common shares to employees and 23,332 shares to consultants[190] - 12,224 common shares were issued upon option exercise for $7,558 aggregate consideration, relying on Rule 701 and Section 4(a)(2) exemptions[191][192] - The IPO, effective October 1, 2020, generated $39.0 million gross proceeds from 3,250,000 common shares at $12.00/share[193] - Net proceeds from the IPO were $36.3 million after underwriting discounts, with $33.8 million remaining after other offering expenses, to be used as described in the IPO prospectus[194] Item 3. Defaults Upon Senior Securities The company reported no defaults upon senior securities - There were no defaults upon senior securities[196] Item 4. Mine Safety Disclosures This item is not applicable to Immunome, Inc - Mine Safety Disclosures are not applicable to the company[198] Item 5. Other Information The company reported no other information required under this item - No other information is reported under this item[199] Item 6. Exhibits This section lists all exhibits filed with the Form 10-Q, including organizational documents, equity-related agreements, indemnity agreements, incentive plans, employment agreements, consulting agreements, license agreements, and certifications - The exhibit index includes organizational documents (Amended and Restated Certificate of Incorporation, Bylaws), common stock certificates, and investor rights agreements[202] - Equity-related exhibits cover preferred stock warrants, various equity incentive plans (2008, 2018, 2020 Plans, ESPP Plan), and forms of stock option grant notices[202] - Other exhibits include indemnity agreements, employment and consulting agreements, several license agreements (e.g., with Arrayjet Limited, MIT, Thomas Jefferson University, PH Pharma Co Ltd), and the DoD OTA Agreement[202][204][206] - Certifications from the Chief Executive Officer and Chief Financial Officer pursuant to Sarbanes-Oxley Act sections 302 and 906 are also included[206]